Objective To assess the impacts of inclusion of care for spontaneous demands in the treatment of hypertensive patients in primary health care. Methods Third generation qualitative assessment survey conducted with 16 workers in a Primary Care Health Unit (PHCU) of the city of Fortaleza, state of Ceara, in the period between July and September of 2015. To collect data, systematic field observation and semi-structured interviews were used, and the stages of thematic content analysis were adopted for data analysis. Results Participants revealed that access, connection and care are fundamental to the treatment of hypertension. However, they said that the introduction of free access for spontaneous demands compromised the flow of care in the hypertension programs. Conclusion A dichotomy between the practice of care recommended by health policies and the one existing in the reality of PHCUs was shown, causing evident losses to the care of hypertensive patients in primary care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/1983-1447.2016.02.60015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sex Differences in the Impact of BMI on Length of Hospital Stay in Hypertensive Patients Admitted to a Cardiology Department: A Retrospective Cohort Study.
Vasc Health Risk Manag
December 2024
Department of Emergency Medical Service, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland.
Background And Purpose: Body mass index (BMI), as a straightforward measure, is widely used in clinical practice, and its results are linked to HT and patient prognosis. This study aimed to ascertain if sex differences exist in the prognostic significance of BMI at the time of admission to the cardiology unit, and how this impacts the LOHS for patients suffering from hypertension.
Patients And Methods: A retrospective analysis of the medical records of 486 patients admitted urgently with a diagnosis of HT to the Cardiology Department at University Hospital in Wroclaw (Poland) between January 2017 and June 2021 was conducted.
The specific medications for pulmonary arterial hypertension at functional class III to IV: a systematic review and meta-analysis.
Front Med (Lausanne)
December 2024
Department of Cardiology, The University-Town Hospital of Chongqing Medical University, Chongqing, China.
Purpose: To systematically evaluate the clinical efficacy and safety of targeted drugs in patients with pulmonary arterial hypertension (PAH) with cardiac function grades III-IV, and conduct a meta-analysis.
Methods: Two researchers independently searched the PubMed, EMBASE, and Cochrane Library databases for relevant studies, with the search period extending from the establishment of the databases to March 2024. Meta-analysis was performed using statistical software Review Manager 5.
Burden of comorbidities in heart failure patients in Türkiye.
Turk J Med Sci
December 2024
Department of Cardiology, Faculty of Medicine, Mersin University, Mersin, Turkiye.
Background/aim: Heart failure (HF) is associated with a wide range of comorbidities that negatively impact clinical outcomes and cause high economic burden. We aimed to evaluate the frequency and burden of comorbidities in HF patients in Türkiye and their relationships with patients' demographic characteristics.
Materials And Methods: Based on ICD-10 codes in the national electronic database of the Turkish Ministry of Health covering the entire population of Türkiye (n = 85,279,553) from 1 January 2016 to 31 December 2022, data on the prevalence of comorbidities in HF patients were obtained.
Metabolomic Profiling Reveals Biomarkers in Coronary Heart Disease Comorbidity.
J Diabetes Res
December 2024
Translational Pharmaceutical Laboratory, Jining First People's Hospital, Shandong First Medical University, Jining, Shandong, China.
Coronary heart disease (CHD), hypertension (HTN), depression (Dep), and Type 2 diabetes mellitus (T2DM) are often comorbid, resulting in an exacerbated patient condition and worsened prognosis. A lack of systematic metabolomic studies on comorbidities of CHD remains. Therefore, comprehensive metabolomic-based evaluation of comorbidities of CHD is necessary.
View Article and Find Full Text PDFRevisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy.
Transgend Health
December 2024
Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5-30 mg every 2 weeks or 2-10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!